Researchers from Zhejiang institutions and international collaborators have published a comprehensive review in the International Journal of Nanomedicine addressing peptide-mediated intracellular delivery of biomacromolecular therapeutics. The review, published in October 2026, systematically examines how peptides can overcome critical barriers in precision medicine, including inefficient cell membrane translocation, endosomal and lysosomal entrapment, and inadequate targeting of specific subcellular organelles. The authors highlight peptides as versatile functional modules for intracellular delivery due to their programmable sequences and tunable biological functions. Unlike previous reviews focusing on isolated aspects such as cell-penetrating peptides, peptide-drug conjugates, or peptide-functionalized nanocarriers, this work provides an integrated overview of the entire intracellular delivery cascade. The review emphasizes mechanisms underlying cell-specific targeting, membrane translocation, endosomal escape, and precise delivery of bioactive molecules to target organelles. This comprehensive analysis is significant for advancing the clinical translation of nucleic acid and protein therapeutics for treating complex diseases in the era of precision medicine.

Lipid nanoparticles (LNPs) represent a transformative delivery platform for cancer vaccines, building on their proven success in COVID-19 immunization. This article examines recent advances in LNP design and engineering specifically tailored for oncological applications. Key developments include the optimization of ionizable lipids and degradable formulations that enhance safety and efficacy while reducing systemic toxicity. The article explores multiple vaccine strategies delivered via LNPs, including personalized mRNA-based neoantigen vaccines, self-amplifying and circular RNA platforms, and peptide or protein combination approaches. Critically, it addresses tissue and immune cell-selective delivery mechanisms, such as targeting antigen-presenting cells and achieving extrahepatic distribution, which maximize therapeutic impact while minimizing off-target effects. The research emphasizes LNP-mediated immune modulation and combination therapy strategies, demonstrating how LNPs can co-deliver multiple immunological agents to enhance T-cell immunity and overcome tumor resistance. These advances position LNPs as a cornerstone technology for next-generation personalized cancer immunotherapy, offering significant clinical potential for improved patient outcomes across multiple malignancies.

Breast cancer brain metastasis represents a significant clinical challenge, particularly in triple-negative and HER2-positive cases, with limited treatment efficacy due to the blood-brain barrier and complex tumor microenvironment. This review, published in the International Journal of Nanomedicine by researchers at Shaoxing People's Hospital, examines exosomal-based anti-cancer therapies as an emerging therapeutic approach. Exosomes are extracellular vesicles measuring 30-150 nanometers that facilitate intercellular communication through transport of proteins and nucleic acids. The article details how exosomes contribute to brain metastasis through multiple mechanisms, including blood-brain barrier remodeling, pre-metastatic microenvironment establishment, and immune evasion via exosomal PD-L1 expression. Importantly, genetically and chemically engineered exosomes show promising targeting and drug-delivery capabilities in preclinical models. This therapeutic strategy addresses critical limitations of conventional chemotherapy and immunotherapy, offering potential to overcome biological barriers that currently restrict treatment effectiveness. The findings underscore exosomal engineering as a viable avenue for developing innovative anti-cancer interventions specifically targeting breast cancer metastasis to the brain.

The intratumoral microbiota—bacteria residing within tumors—plays an increasingly recognized role in cancer immunotherapy outcomes. This review examines the complex metabolic-epigenetic crosstalk between tumor-associated microorganisms and cancer cells, revealing how bacterial metabolites influence epigenetic modifications that affect immune response activation. The research explores how specific bacterial species modulate histone acetylation and DNA methylation patterns, thereby enhancing or suppressing anti-tumor immunity. Beyond understanding natural microbial effects, the article discusses engineered bacterial therapeutics as an emerging treatment strategy, where genetically modified bacteria are designed to produce immunostimulatory molecules or directly target cancer cells. These engineered systems represent a frontier in precision oncology, offering potential synergy with existing checkpoint inhibitors and conventional therapies. Understanding this metabolic-epigenetic interface is critical for optimizing cancer immunotherapy efficacy, as it identifies new targets for intervention and explains variable patient responses to treatment, ultimately advancing personalized cancer medicine approaches.

GeoVax Labs announced a stock offering expected to generate approximately $4.63 million in net proceeds, comprising the sale of up to 29.6 million shares of common stock or pre-funded warrants at assumed prices of $0.169 per share and $0.168 per warrant, respectively. The company intends to allocate these funds primarily toward product development, including the planned Phase 3 GEO-MVA trial, alongside other corporate purposes and up to $2.5 million for marketing and advertising services. The underwriter has the option to purchase additional shares and warrants for over-allotments within 45 days. However, the offering occurs amid significant financial headwinds: GeoVax's auditors expressed substantial doubt about the company's going concern status, and Nasdaq initiated delisting proceedings after the stock traded below $1.00 for 30 consecutive business days, though GeoVax requested a hearing that stayed further action. Additionally, a recent revolving credit agreement grants lender-designated directors a majority position on GeoVax's board despite no borrowing to date, raising governance considerations for investors.

Engineered extracellular vesicles (EVs) derived from pluripotent stem cells (PSCs), including embryonic stem cells and induced pluripotent stem cells (iPSCs), represent an emerging frontier in regenerative medicine. These vesicles mediate cellular communication by transferring bioactive molecules essential for cell signaling. Compared to traditional cell therapies, engineered EVs demonstrate significant advantages including reduced immunogenicity, enhanced targetability, and improved stability. The review examines diverse therapeutic applications across angiogenic, tissue restorative, immunomodulatory, and gene therapy domains. iPSC-derived engineered EVs show particular promise in regenerating cardiac, bone, cartilage, and corneal tissues while simultaneously enabling drug delivery systems and disease diagnostics via biomarker identification. Hydrogel-integrated EV systems provide depot-based controlled release mechanisms that enhance tissue repair outcomes. These engineered vesicles also facilitate targeted drug delivery to specific sites and improve diagnostic imaging through enhanced contrast. The expanding potential of engineered PSC-EVs positions them as versatile tools for developing novel therapeutic approaches across multiple biomedical applications, with future research aimed at deepening understanding of their mechanisms and clinical translation possibilities.

CD Bioparticles provides custom bioparticle production services utilizing advanced bionanotechnology platforms. Immunoliposomes, which are liposomes with antibodies attached to their membrane surfaces, represent a promising targeted drug delivery system designed to reduce side effects by enabling selective uptake by cells overexpressing specific antigens. Antibodies or ligands can be attached to liposomes through either covalent or noncovalent binding methods, applied before or after liposome preparation. Covalent attachment typically involves sulfhydryl groups on antibody molecules, which are either generated through disulfide reduction or thiolation agents, then reacted with maleimide-containing lipids to form thioether linkages. Alternatively, ligands can be bound noncovalently using biotin-neutravidin or streptavidin interactions. The functionalization can occur either pre-incorporation through ligand-anchor coupling or post-incorporation on the liposomal surface. Immunoliposomes represent a significant advancement in targeted therapeutics with demonstrated applications across cancer therapy, inflammatory diseases, and cardiovascular disease treatment, offering improved therapeutic efficacy while minimizing adverse effects through their precision targeting capabilities.

Researchers at Sapienza University of Rome and the University of Milan have developed pH-sensitive liposomes that dramatically alter their behavior in acidic environments, with findings published in Frontiers in Bioengineering and Biotechnology. The nanoscale lipid vesicles, assembled via microfluidics from unsaturated phospholipid DOPE and stabilized with oleic acid, were decorated with cyclic RGD targeting peptides. Through comprehensive physical measurements tracking particle size, bilayer structure, membrane fluidity, and cargo release across pH levels from 7.4 to 4.4, the team demonstrated that vesicles remain stable at physiological pH but progressively destabilize under the mildly acidic conditions found in late endosomes and lysosomes. This addresses a critical drug delivery challenge: conventional liposomes release cargo too slowly and often trap payloads in endosomal compartments. The pH-responsive design enables stability in the bloodstream while triggering release in acidic tumor microenvironments and cellular compartments. At neutral pH, oleic acid's deprotonated carboxylate maintains electrostatic repulsion with DOPE phosphate groups, stabilizing the bilayer; protonation at lower pH weakens this interaction, initiating membrane destabilization and payload release.

Researchers from Indian medical institutions conducted a systematic review examining how non-coding RNAs (ncRNAs) regulate the tumor immune microenvironment in breast cancer, addressing a critical challenge in immunotherapy resistance. The study analyzed 63 eligible research articles from PubMed, Web of Science, and Scopus databases to understand mechanisms by which ncRNAs—including microRNAs, long non-coding RNAs, and circular RNAs—influence tumor-associated macrophages (TAMs) and immune suppression. The analysis revealed that diverse ncRNA classes converge on five key signaling pathways: PI3K/AKT/mTOR, JAK/STAT3, NF-κB, TGF-β, and hypoxia-associated pathways. These pathways drive M2-like TAM reprogramming, promoting immune suppression, tumor progression, angiogenesis, metastasis, and resistance to immunotherapy. Notably, specific tumor-suppressive ncRNAs demonstrated the opposite effect, promoting M1-like TAM polarization and enhancing anti-tumor immunity. The researchers developed a translational prioritization model ranking ncRNAs based on polarization evidence, mechanistic depth, and in vivo validation. This work identifies therapeutic targets for rewiring the immunosuppressive breast cancer microenvironment and potentially overcoming immunotherapy resistance.

Extracellular vesicles (EVs), including exosomes, serve as intercellular communicators carrying molecular signatures from their donor cells that direct their interactions with recipient cells and determine tissue distribution. This review synthesizes current knowledge on how EV surface proteins influence cellular docking, uptake, and signaling while examining their roles in immune regulation, tumor cytotoxicity, metastatic progression, and immune evasion. The authors assess EV-associated surface signatures as potential liquid-biopsy biomarkers for disease detection, staging, prognosis, and treatment monitoring. Surface engineering approaches have demonstrated promise in preclinical models for enhancing tissue accumulation and therapeutic cargo delivery, while blocking pathogenic EV-cell interactions offers an alternative therapeutic strategy. However, advancing clinical translation requires standardized isolation and characterization protocols, resolution of EV heterogeneity at single-vesicle resolution, reproducible biodistribution data, scalable manufacturing processes, and rigorous safety and efficacy evaluation. Understanding how surface-associated features operate within this complex multifactorial system is essential for clarifying disease mechanisms and developing precise EV-based diagnostics and therapeutics.

Smart drug delivery systems (SDDS) represent an advanced approach to transporting therapeutic agents throughout the body with enhanced precision and safety. Unlike conventional drug delivery methods, SDDS can autonomously sense internal signals such as pH levels, enzyme activity, and molecular concentrations, or respond to external stimuli including light, magnetic fields, and ultrasound to release medications at optimal times and locations. The primary objective is administering the correct dose to the intended site at the precise moment in a controlled manner, thereby maximizing therapeutic efficacy while minimizing side effects and improving patient adherence. Key nanocarriers utilized in these systems include liposomes, nanospheres, quantum dots, dendrimers, carbon nanotubes, and superparamagnetic iron-oxide nanoparticles. SDDS technology addresses critical challenges in traditional drug delivery, such as poor dissolution, enzymatic degradation, rapid clearance, and toxicity to healthy cells, while enabling drugs to cross physiological barriers effectively. The field traces its origins to Tanaka's 1978 polyacrylamide gel research and early thermosensitive liposome developments, establishing a foundation for modern intelligent pharmaceutical delivery systems that enhance treatment outcomes while reducing overall healthcare costs.

Researchers from Jilin Cancer Hospital and Tongji University have developed an innovative nanoplatform, R-DCPA-GPL-LNP@mET, to address triple-negative breast cancer (TNBC), which remains clinically challenging due to tumor heterogeneity and immunosuppressive microenvironments that limit checkpoint blockade efficacy. The dual-responsive lipid nanoparticle co-delivers multiplexed mRNAs encoding bispecific macrophage engagers targeting both EGFR and TROP2, comprehensively engaging heterogeneous tumor cells. The platform features pH-responsive charge-reversal lipid DCPA for enhanced endosomal escape in acidic tumors and a GSH-cleavable anti-PD-L1 antibody for tumor-selective immunotherapy release. In orthotopic 4T1 TNBC mouse models, the nanoplatform reprogrammed tumor-associated macrophages toward tumoricidal phenotypes while triggering robust phagocytosis, neutralized oncogenic signaling pathways, and synergized with anti-PD-L1 to recruit cytotoxic T lymphocytes and Natural Killer cells while depleting immunosuppressive myeloid-derived suppressor cells. Results demonstrated marked tumor regression with favorable safety profiles over 22 days, supporting further development as a promising strategy for heterogeneous solid tumors.

Researchers at MIT have developed a novel approach to cellular immunotherapy that could dramatically simplify and reduce the cost of treating blood cancers and autoimmune diseases. Published in Nature Biotechnology, the study describes lipid nanoparticles engineered to deliver messenger RNA directly to natural killer cells within the body, reprogramming them to target cancerous or dysfunctional T cells. In mouse models, this single-injection strategy achieved complete remissions in aggressive melanoma, eliminated T cell lymphoma tumors, and healed liver damage in autoimmune hepatitis. The advancement addresses a critical bottleneck in current CAR T cell therapies, which require time-consuming and expensive manufacturing processes involving cell extraction, engineering, and expansion outside the body. Natural killer cells offer distinct advantages over engineered T cells, particularly for treating T cell malignancies and autoimmune conditions, since they can eliminate dysfunctional T cells without destroying themselves through fratricidal conflict. This in vivo reprogramming approach could substantially accelerate treatment timelines and accessibility while maintaining therapeutic efficacy.

Immune checkpoint inhibitors have revolutionized treatment for mismatch repair-deficient colorectal cancer, yet approximately ninety-five percent of patients with mismatch repair-proficient disease experience minimal benefit due to immunologically "cold" tumor microenvironments, limited T-cell infiltration, and systemic immunosuppression, particularly in hepatic metastases. Existing clinical approaches combining multikinase inhibitors with anti-PD-1 therapy, dual checkpoint blockade, chemotherapy, or antiangiogenic agents have yielded modest and largely non-durable responses. This comprehensive review, published in the International Journal of Nanomedicine by researchers at China Medical University, synthesizes evidence on nanotechnology-enabled immunotherapy for colorectal cancer. The authors distinguish between clinically established evidence, early-phase clinical strategies, and preclinical concepts, aiming to develop a biomarker-enriched translational research agenda. By focusing on pharmacological remodeling of the tumor microenvironment rather than solely releasing checkpoint restraint, nanotechnology-based approaches offer promising potential to overcome current therapeutic limitations and improve outcomes in this treatment-resistant patient population.

Drug delivery systems have undergone significant transformation, evolving from traditional formulations toward sophisticated smart and artificial intelligence-assisted technologies. This transition represents a paradigm shift in pharmaceutical science, addressing limitations of conventional approaches such as poor bioavailability, systemic toxicity, and lack of targeted efficacy. Modern smart delivery systems utilize stimuli-responsive mechanisms, including pH-sensitive, temperature-responsive, and enzyme-triggered platforms, enabling precise drug release at disease sites. Integration of artificial intelligence has revolutionized the field by optimizing formulation parameters, predicting drug behavior, and personalizing treatment strategies through machine learning algorithms. Nanotechnology platforms, including liposomes, nanoparticles, and micelles, enhance drug stability and cellular uptake while reducing adverse effects. These advancements enable lower dosing requirements, improved patient compliance, and enhanced therapeutic outcomes. The convergence of smart materials and AI analytics represents a critical advancement in precision medicine, positioning next-generation drug delivery as essential for treating complex diseases including cancer, neurological disorders, and chronic conditions where conventional therapies prove inadequate.

Researchers have developed an innovative therapeutic approach to address the challenge of metastatic and castration-resistant prostate cancer by engineering mesenchymal stem cell-derived extracellular vesicles (EVs) to selectively target and deliver therapeutic cargo. The platform utilizes PSMA-targeting single-chain variable fragments (PSMA-scFv) to enable precise delivery of small interfering RNA against ADAM9 (siADAM9), a key regulator implicated in tumor progression and adaptive androgen receptor signaling. In both hormone-sensitive LNCaP and castration-resistant CWR22Rv1 prostate cancer models, EV-mediated siADAM9 delivery effectively suppressed ADAM9 expression and inhibited malignant phenotypes including proliferation, migration, and tumor sphere formation. The treatment also reversed epithelial-mesenchymal transition and stemness-associated molecular programs while disrupting downstream signaling pathways involving AKR1C3-mediated androgen biosynthesis. Notably, EV-siADAM9 enhanced the efficacy of androgen-targeted therapies, including androgen deprivation therapy and abiraterone in both disease contexts. These findings demonstrate proof-of-concept for PSMA-targeted EV platforms as a promising strategy to overcome treatment resistance in advanced prostate cancer, warranting further preclinical development.

Smart drug delivery systems (SDDS) represent an advanced approach to therapeutic administration, designed to autonomously sense physiological signals and release medication at precise locations and times with minimal external intervention. These systems respond to external triggers such as light, magnetic fields, or ultrasound, as well as internal signals including pH levels, enzyme activity, and molecular concentrations. Key nanocarriers employed in SDDS include liposomes, nanospheres, quantum dots, dendrimers, carbon nanotubes, and superparamagnetic iron-oxide nanoparticles. The fundamental objective is delivering the correct drug dosage to the intended site at the optimal moment, maximizing therapeutic efficacy while minimizing side effects and improving patient compliance. SDDS address critical challenges including poor drug dissolution, enzymatic degradation, rapid clearance, and cellular toxicity. Landmark developments include Tanaka's 1978 polymer gel research and concurrent thermosensitive liposome discoveries. An effective SDDS should remain stable in biological fluids, avoid immune responses, achieve proper cellular targeting, and maintain biocompatibility. This technology promises improved treatment outcomes, reduced toxicity, lower healthcare costs, and enhanced patient adherence to therapeutic regimens across multiple medical applications.

# Summary This article presents a comprehensive review of nanoparticle-enabled immune-dose shaping strategies in breast cancer treatment. The research examines how nanoparticles can be leveraged to optimize immunological outcomes during radiotherapy by modulating radiation-induced effects on both tumoral and systemic immunity. The study employs a structured translational evidence hierarchy to classify nanoparticle dose-exchange evidence and evaluates the dual immunological consequences of breast radiotherapy: tumor local immunogenicity resulting from radiation damage and adaptive immune activation, alongside systemic immune-cell depletion from lymphopenia. A critical finding is that tumor immunogenicity and lymphocyte preservation must be assessed simultaneously to optimize therapeutic benefit. The review also analyzes radiation-induced lymphopenia's clinical significance in breast cancer patients, including its incidence, severity, and kinetics. This work matters because it establishes a framework for developing nanotechnology-based interventions that can enhance anti-tumor immunity while mitigating radiation's immunosuppressive side effects, potentially improving clinical outcomes for breast cancer patients undergoing radiotherapy combined with immunotherapeutic approaches.

A Nature Biotechnology study published October 13, 2026 presents a significant advancement in CAR-NK cell therapy by shifting genetic engineering from ex vivo manufacturing to in vivo modification. Researchers used ligand-directed lipid nanoparticles (LNPs) decorated with engineered antibody fragments (scFvs) targeting NK-cell receptors like NKG2D and NKG2A to deliver CAR-encoding mRNA directly into patients' natural killer cells. In preclinical mouse models, this approach demonstrated efficient mRNA delivery and functional activity in B-cell depletion, autoimmune hepatitis, and tumor elimination. This represents a paradigm shift from traditional time-consuming and expensive cell collection, modification, and expansion protocols. However, critical questions remain about clinical applicability, particularly regarding NK-cell availability in immunocompromised cancer patients and the durability of engineered cells. The technology's true therapeutic value depends on understanding cell proliferation, tumor migration, longevity, and whether in vivo CAR-NK engineering provides durable immune protection or requires repeated administration rather than sustained immunity.

# Summary Stimuli-responsive nanocarriers represent a significant advancement in targeted drug delivery systems, addressing the critical challenge of delivering therapeutic agents precisely to disease sites while minimizing systemic exposure. These innovative nanoparticles are engineered to release their payload in response to specific environmental triggers such as pH changes, temperature fluctuations, light exposure, or enzyme activity. The technology leverages the distinct physiological conditions of diseased tissues—particularly the acidic microenvironment of tumors—to achieve selective drug release at target locations. By incorporating stimuli-responsive polymers and lipid-based materials into nanocarrier designs, researchers have demonstrated enhanced therapeutic efficacy and reduced off-target effects compared to conventional drug delivery methods. This approach is particularly valuable for cancer treatment, where controlled release improves drug bioavailability at tumor sites while protecting healthy tissues from toxic exposure. The development of these sophisticated delivery systems has profound implications for personalized medicine and represents a paradigm shift toward more effective and safer therapeutic interventions across multiple disease categories.